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44 The Journal of Thoracic and Cardio“In certain cases of angina pectoris, when the mouth of the coronary arteries
is calcified, it would be useful to establish a complementary circulation for the
lower part of the arteries.”
Alexis Carrell, 1910
he concept of coronary revascularization has existed for a century now, since
Alexis Carrell’s seminal experimental procedure, in which the left subcla-
vian artery was suture-anastomosed to the circumflex coronary artery in the
og.1,2 The latter half of the century witnessed an explosion in techniques of
oronary revascularization, both in cardiac surgery and interventional cardiology.
ith analysis of long-term outcomes, the clinical benefits of restoring coronary flow
re now well-established, including improved quality of life and better long-term
urvival. In the past decade, however, multiple methods of coronary revasculariza-
ion have emerged, creating confusion about the best technique in a given patient.
linical approaches have been on a veritable roller coaster, leading to fractionation
f therapeutic recommendations and controversy. As stated by Dr. John W. Kirklin
n his 1972 Lewis A. Conner lecture before the American Heart Association3:
When [physicians] embark upon an intervention for their patient, they must do so
ith confidence and conviction if there is to be a high probability of success. But
hese very convictions can make the doctor guilty of premature conviction in
valuating procedures, unless he addresses this evaluation with the same seriousness
nd skill he uses in treating individual patients”. With recent objective assessments,
airly uniform data now are emerging to guide decision-making, and relevant issues
and at least some answers) are becoming more consistent. The purpose of this
ditorial is to review briefly this new information, within the context of the article
n this issue by Guru and associates,4 and to present a viewpoint, based on the
uthors’ interpretation of current data.
Very early after the clinical introduction of surgical coronary bypass, a major
tudy was begun, the Veterans Administration (VA) randomized trial.5 It should be
mphasized that this was an early era both in clinical research and in the techniques
f coronary bypass. We now forget that the first major randomized trial in surgery
ad been published only a few years earlier,6 and that statistical methods such as the
ox model for observational studies had not yet been described.7 By today’s
tandards, surgical techniques for coronary bypass also were rudimentary. Despite
hese limitations, the VA trial did show a significant survival benefit after coronary
ypass in patients with left main coronary disease, primarily because the surgical/
edical treatment benefit was so large that it could be defined even with a small
ample. The next 3 major trials were: 1) the Unstable Angina Trial, 2) the European
oronary Surgery Study, and 3) the Coronary Artery Surgery Study (CASS). Each
f these trials examined coronary bypass versus medical therapy in non-left main
atients with predominantly good ventricular function, each had recruitment prob-
ems, and all probably were underpowered.8-10 Moreover, the results of these trials,
rguably, were interpreted in over-simplified and possibly counterproductive
ays,11 to support the concept that coronary bypass had no survival benefit in
on-left main patients and to suggest that a delayed approach to coronary revascu-
arization was appropriate in most situations. These studies also illustrated the
vascular Surgery ● May 2006
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Limitations of randomized trials in cardiovascular disease:
xcessive cost, recruitment difficulties, selection of poten-
ially unrepresentative patients at the point of randomiza-
ion, the necessity of crossover design for patient care (and
ts negative effects on statistical power), the ability to assess
reatment at only one point in time, and the potential for
uperficial misinterpretation of the data. To this list can be
dded new problems encountered in more recent trials, such
s STICH: the reluctance of physicians to contribute pa-
ients in a financially stressed environment and the now
xcessive cost of malpractice insurance for prospective clin-
cal research. While randomized study design minimizes base-
ine differences and confounding influences in patient cohorts,
t should not be viewed (as in the Guru paper) as any type of
gold standard”. Randomized clinical trials require proper
crutiny and interpretation, just like any other clinical research.
By the mid-1980’s, statistical methodology for observa-
ional studies had improved considerably, especially with
he development of the Cox proportional hazards model.
hen coupled with prospective data collection, such as em-
loyed in Duke Cardiovascular Databank studies, the Cox
odel allowed entire clinical populations to be assessed, at
inimal additional cost, over extended periods of time, and
ith better understanding of (and compensation for) treatment
election biases. Hlatky and associates12 demonstrated that in a
ell-understood area such as coronary artery disease, and with
he availability of powerful prognostic variables, an inclusive
atient cohort, and nearly complete followup, predictions of
urvival with medical versus surgical therapies were in excel-
ent agreement between randomized and observational publi-
ations. Observational methodology, to be sure, also had lim-
tations, but by 1984, the results suggested a significant
urvival benefit after coronary bypass grafting in all patients
ith multi-vessel coronary artery disease.13 Interestingly in
he Duke data, surgical survival characteristics have been
table since the mid-80’s (unpublished observations, Dr.
eter K. Smith and Mr. Robert Tuttle, 2005), and early
tudies designed to assess the clinical benefits of multiple
nternal mammary artery (IMA) bypass grafting proved
egative at initial follow-up.14
More recent surgical innovation addressed the potential
dvantages of off-pump coronary bypass. While this method
ad been used for some time, a major effort was made to
mprove technical details and to extend the procedure into
atients with more complex disease. With considerable data
oming in at present,15 off-pump bypass probably improves
arly results negligibly, and several studies suggest that
ong-term outcomes could be inferior,16,17 perhaps because
f problems with myocardial protection, the tendency to
nder-graft, and at times, compromised graft quality. While
his subject is still unresolved and is undergoing consider-
ble debate, in the author’s view, off-pump bypass probably i
The Journal of Thoracicill not be associated with large advantages in the manage-
ent of patients with coronary artery disease.
Another major effort at quality improvement was the
evelopment of percutaneous coronary interventions (PCI).
volving over 2 decades from balloon angioplasty alone, to
therectomy, to bare-metal stents, and now to drug eluting
tents, PCI has engendered an enormous developmental
ffort on the part of industry and cardiology investigators.
his evolution has been accompanied by a reduction in
arly complications, to the point that PCI procedures now
re rarely associated with acute problems. Advanced inter-
entional techniques have contributed significantly to the
are of patients with acute myocardial infarction and other
cute coronary syndromes. Because of the perception that
estenosis rates are much lower (a concept based primarily
n 6-12 month follow-up data), drug eluting stents currently
re being used in increasingly complex clinical settings, to
he point that national rates of coronary bypass surgery are
alling. PCI does have the advantage of less invasive meth-
dology and diminished patient trauma, but do the available
ong-term clinical data justify this massive expansion in
pplication?
In BARI trial studies of balloon angioplasty,18 and also
n more recent analyses of bare metal stents,19,20,21,22 long-
erm death rates after PCI were significantly higher than
hose observed for coronary bypass. Along these lines, the
ARI trial illustrated several points. First, like CASS,
ARI largely enrolled low-risk patients with good out-
omes. With low event rates, therapeutic differences may
ave been difficult to define with the trial sample size. At
he outset, the surgical committee of BARI (chaired by Dr.
loyd Loop) was concerned about this problem, and nego-
iated for liberalizing enrollment criteria. Ultimately, the
oncept emerged from BARI that coronary bypass was
ore effective than PCI only in diabetics, based on a pos-
tive treatment interaction term (P  0.042). However, it is
lso possible that “diabetes” was a surrogate for higher
eneral baseline risk, and that the surgical outcome benefit
n diabetics was a reflection (to some extent) of better
esults in the higher risk population.18 The more recent
oncept that PCI is associated with twice the relative long-
erm death rate as coronary bypass across the entire spec-
rum of baseline risk (manifested as small absolute differ-
nces in low-risk patients and large absolute differences in
igh-risk patients) may be the operative principle.19,22 This
obering fact should bring pause to the general application
f PCI, especially considering the projected number of
atients who may have died because of PCI over-utilization.
ssessment of drug-eluting stents is under-way at present,
ost notably in the BARI 2D trial, comparing medical with
urgical and PCI therapies in patients with Type 2 diabetes.
he beginning of this trial fortuitously coincided with thentroduction of drug eluting stents; the results, therefore,
and Cardiovascular Surgery ● Volume 131, Number 5 945
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Lill be very important; and 3-year outcomes in BARI 2D
hould be available shortly. The concept of “hybrid” coro-
ary revascularization, utilizing combinations of minimally
nvasive IMA grafts and simultaneously placed coronary
tents, is a recent variation on the PCI theme. It is likely that
he poor performance of coronary stents may be a limiting
actor with this approach,23 but more long-term data are
eeded. Finally, the problem of late sudden death seen with
rug eluting stents in clinical practice is very concerning,
nd it is hoped that scientific data will soon be available as
guide. Many are concerned that self-referral and financial
ncentives have played at least some role in the rapid ex-
ansion of PCI, and it would be useful to recall Dr. Kirklin’s
dmonitions when considering future therapeutic options.
Throughout this evolution of approaches, Dr. Bruce Lytle
nd associates at the Cleveland Clinic continued to espouse the
dvantages of bilateral internal thoracic artery bypass.24,25
ven when most data were to the contrary, Drs. Lytle and
lackstone applied a newer observational technique, propen-
ity score matching, to the assessment of this problem. Pro-
ensity analysis has been a breakthrough in comparing treat-
ents in observational studies.26-28 By liberally modeling
endencies for non-random treatment selection using all
vailable baseline variables (significant or not), the propen-
ity model (estimated probability that a patient will get a
pecific treatment) captures all measured confounders into a
ingle variable. Propensity analysis can be considered a data
eduction technique in which more confounders can be
djusted than there are deaths. It can be accompanied by a
ensitivity analysis to assess whether an observed treatment
ffect can easily be explained by an unmeasured confounder;
hus, propensity modeling allows much more aggressive
djustment for confounding variables than previously pos-
ible. Using these methods, data from multiple sources are
ecoming available, including the paper of Guru and asso-
iates, and most studies verify Dr. Lytle’s hypothesis. Dr.
uru’s analysis also illustrates several important designnnovations, including the linking of multiple national da- b
46 The Journal of Thoracic and Cardiovascular Surgery ● Mayabases. While refinements will need to be made, employing
similar technique of linking the ACC and STS databases
o the National Death Index could facilitate clinical cardio-
ascular research in heretofore unimagined ways. It would
e necessary to fulfill HIPAA requirements in order to
aintain patient identifiers in the STS database, but efforts
hould begin in this direction. Additionally, consideration
hould be given to using the STS database as the platform
or generating more cost-effective randomized trials in car-
iac surgery. Since the first goal of establishing the STS
atabase has been achieved, future modifications might be
irected toward significantly enhancing national clinical
esearch. The key is continued improvement in database
ccuracy, validity, and completeness.
The Guru study also illustrates the importance of com-
osite outcomes. It is now understood that outcomes are
ultivariate and inter-related, as in the concept of compet-
ng risks.29 These new insights and other very important
mprovements in observational analyses are in their early
evelopment. An example is analysis of dynamic or time-
arying treatments. It is often the case that a treatment
annot be assigned to patients at the time of diagnosis
ithout subsequent additional therapies being applied or
ithdrawn. Thus, attempting to compare dynamic treatment
egimens can be extremely difficult. Some promising meth-
ds,30-32 including time-varying propensity scores, are now
vailable and undoubtedly will be applied to the complex
ituations seen in current practice. Highly sophisticated
bservational approaches, performed on large and compre-
ensive patient populations, offer great promise for the
uture, and as these methods are developed, the current
rend toward generalizing research at the national level
ould rapidly accelerate clinical observations. Needless to
ay, the availability of virtually on-line, large-scale, and
ven more precise national databases in every aspect of
ardiovascular disease could bring the reality of “evidence-
Figure 1. Composite outcomes of all-cause
mortality, non-fatal MI, PCI, and redo coronary
bypass were significantly reduced in multi-
vessel coronary disease patients undergoing
multiple IMA grafting to 2 different coronary
systems (as compared to single IMA grafting)
at 20-years of followup.ased medicine” to daily bed-side decision making.
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LReturning to the Guru paper, few now would question the
enefits of multiple IMA bypass in patients with multi-
essel coronary disease. Long-term mortality is reduced,
on-fatal myocardial infarction and PCI occur at a lower
ate, and the incidence of reoperation is dramatically less.33
n the authors’ study (Figure 1) with a mean follow-up to
0-years,34 average event-free life expectancy was extended
y almost one year, and on average, one patient in five
enefited clinically. Only 4.6% of multi-vessel patients un-
ergoing multiple IMA grafting required redo coronary
ypass over 20-years, as compared to 12.6% of single IMA
atients. This result is different from the Guru study, but the
ifference may in fact illustrate that outcomes are multivar-
ate and interrelated. Within the U.S. healthcare system with
ts greater surgical availability, worse long-term results with
ingle versus multiple arterial grafting might be manifested
y a relatively higher incidence of reoperation and less of a
ifference in mortality. Conversely, care limitations in Can-
da might be associated with a lower incidence of reoperation
nd a higher mortality. This point emphasizes the propriety of
omposite outcome, but in any event, the debate about multiple
MA grafting seems to be over. Whereas, the incidence of
ultiple IMA grafting was low in recent STS data, the rate
ery likely will accelerate at this point. To modestly go out
n a limb, one might even suggest that 50-75% of patients
ith multi-vessel disease now should be managed with
ultiple IMA’s, including patients with diabetes and other
igh-risk profiles.34 It should be emphasized that this con-
ept is not substantiated for radial artery grafts, and one
MA and concomitant radial arteries should not be consid-
red as “all arterial” surrogates for multiple IMA grafting.
ertainly, the inability to differentiate between types of
rterial grafts is a weakness in the study of Guru et al, and
eeds to be remedied in their database. Proven clinical
enefits are associated only with bilateral IMA’s, and with
ecent radial artery patency data, it is unlikely that addition
f radial arteries (while perhaps useful) will produce major
herapeutic benefits.
Finally, one might traverse another limb, and propose a
hange in the treatment algorithm for future patients with
erious multi-vessel coronary artery disease. Given the ex-
ellent long-term outcomes associated with multiple IMA
rafting, and the as yet irrefuted late problems with PCI,
aybe the current management strategy of attempting PCI
rst in most patients is backwards. Perhaps multiple IMA
rafting should be performed as the first procedure in most
atients with serious multi-vessel coronary obstruction, and
hen PCI applied for the unusual situation of graft failure
nd recurrent single vessel disease. It is likely that outcomes
ould be improved with this approach, and long-term cost
fficacy also could be better. Quoting again from Dr.
irklin’s lecture over 3 decades ago3: “If we are able to
rovide the best possible care for all patients coming to us
2
The Journal of Thoracicith heart disease, now and in the future, we must do many
hings, including the continual evaluation of the results of
ur cardiac operations and a comparison of these results
ith those of other patient management programs and with
he natural history of the disease”. In the near future, Dr.
irklin’s vision may become everyday reality.
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